Q-omics provides the consensus-scored PM20D2 profile across patient tissues and cancer cell-line models. PM20D2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PM20D2 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, PM20D2 RNA expression shows 19,962 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where PM20D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PM20D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PM20D2 survival associations across molecular data types. PM20D2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PM20D2 RNA expression–survival associations across cancer types. High PM20D2 expression shows unfavorable associations in LIHC and SCLC, but favorable associations in KIRC, UCS, SKCM and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PM20D2 RNA expression.
This table summarizes PM20D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PM20D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PM20D2 shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in LUAD, LIHC and STAD. The LUAD box plot shows higher PM20D2 RNA expression in tumor versus normal tissue (log2 FC = +0.952, t-test p < 0.001).
This table shows molecular features associated with PM20D2 in patient tissues and cancer cell lines. In patient samples, PM20D2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PM20D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
